Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Book your place for our upcoming virtual conference

18-19 November 2021

17th National Conference of the

Primary Care Diabetes Society (PCDS)

We are delighted to invite you to virtually attend this year’s National Conference of the Primary Care Diabetes Society (PCDS), our annual, free-to-attend, two-day virtual conference taking place on 18-19 November 2021.

While the format remains virtual this year, you will, as ever, be able to benefit from clinically focused education on a range of topics that are most relevant to the practicalities of managing diabetes in primary care today. To name just a few of these, we have experts presenting on mental health, retinopathy, insulin initiation, the diabetic foot, and the all-important new ways-of-working.

We very much hope that you can join us for this key event in the 2021 diabetes calendar.

This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more

  • Ask the experts your burning questions through the LIVE Q&A at the end of each session
  • Log on anytime during the two-days from the comfort of your own home to view the sessions
  • Don’t worry if you miss something, all of the content will be available on-demand
  • Claim 11 CPD points for the two-day virtual conference

Poster abstract

submissions

Poster abstract submissions have now closed for this year.

Submitted abstracts will now be anonymously peer-reviewed and you will receive confirmation of acceptance or non-acceptance via email by mid-October.

Agenda

Day 1

09.15-09.25

Session 1

Chair’s introduction

09.25-09.55

COVID-19 and diabetes: Latest evidence

  • Ongoing challenges for people with diabetes in the COVID era
  • Metabolic factors and long COVID

15 min break

10.10-10.40

Symposia

15 min break

10.55-11.25

Addressing health inequality in a multi-ethnic population

  • Key factors driving the variation in care
  • Cultural and ethnic barriers to diabetes care, and the consequences these can have
  •  Case studies: Engaging effectively with communities

15 min break

11.40-12.20

Session 2

‘In Practice’ masterclasses Rotation 1

1. Severe mental illness and learning difficulties

  • The risk of diabetes in people with severe mental illness
  • Improving diabetes care for people with learning difficulties
  • Resources available to make diabetes education accessible to your patients

2. Older and frail people

  •  Practical guide to identifying patients with frailty
  • Top considerations for prescribing in older and frail people
  • Why, when and how to de-intensify diabetes therapy

3. Sexual health

  • The link between diabetes and male sexual dysfunction
  • Diabetes, polycystic ovary syndrome and sexual health in women
  • Contraception and family planning in people with diabetes – key points to consider

4. Foot care and peripheral arterial disease

  • Conducting a foot assessment remotely Assessing risk and identifying “red flags” for referral
  • How to communicate foot care advice successfully to patients

15 min break

12.35-13.05

Symposia

15 min break

13.20-14.00

Rotation 2

1. Severe mental illness and learning difficulties

  • The risk of diabetes in people with severe mental illness
  • Improving diabetes care for people with learning difficulties
  • Resources available to make diabetes education accessible to your patients

2. Older and frail people

  •  Practical guide to identifying patients with frailty
  • Top considerations for prescribing in older and frail people
  • Why, when and how to de-intensify diabetes therapy

3. Sexual health

  • The link between diabetes and male sexual dysfunction
  • Diabetes, polycystic ovary syndrome and sexual health in women
  • Contraception and family planning in people with diabetes – key points to consider

4. Foot care and peripheral arterial disease

  • Conducting a foot assessment remotely Assessing risk and identifying “red flags” for referral
  • How to communicate foot care advice successfully to patients

15 min break

14.15-14.45

Session 3

Language matters: Overcoming common communication hurdles

  • Adapting your communication strategies for different ages and cultures
  • Addressing health beliefs and understanding health literacy

15 min break

15.00-15.30

Symposia

15 min break

15.45-16.15

Question Time: Individualised lifestyle interventions

  • Panel discussion Q&A
  • What is the role of digital interventions in diabetes care?
  • Motivational interviewing to support lifestyle and behavioural change
  • Local and national resources available for you and your patients

16.15-16.45

AGM session

16.45

Chair’s close

Day 2

09.00-09.10

Session 1

Chair’s introduction

09.10-09.40

Individualised care in the context of multimorbidity

  • The cardiovascular-renal-metabolic axis in diabetes
  • Providing joined-up care to people with long-term conditions

15 min break

09.55-10.25

Symposia

15 min break

10.40-11.10

Connecting the dots in the obesity pathway

  • Weight management services available in the UK
  • Who and how to refer to specialist care
  • The obesity MDT: engaging with other professionals to manage this complex condition

15 min break

11.25-12.05

Session 2

‘In Practice’ masterclasses Rotation 1

1. Top tips for primary care

  • Latest advice on screening for retinopathy
  • The spectrum of liver disease in diabetes
  • Renal impairment – identification, assessment and management

2. Insulin initiation and titration: complex cases

  • Case study-led discussion session
  • Remote management of insulin – how can it be done?
  • Practical guidance on initiating and adjusting insulin therapy

3. Getting primary care back on the road: diabetes care post-COVID-19

  • Prioritisation and addressing the backlog of care
  • Using audits and tools to optimise the use of limited resources
  • Variations in care – how can we begin to address them?

4. Remote consultations for Type 2 diabetes – supporting more effective clinical management

  • Session organised and supported by Abbott
    Laboratories Ltd.

15 min break

12.20-13.00

Rotation 2

1. Top tips for primary care

  • Latest advice on screening for retinopathy
  • The spectrum of liver disease in diabetes
  • Renal impairment – identification, assessment and management

2. Insulin initiation and titration: complex cases

  • Case study-led discussion session
  • Remote management of insulin – how can it be done?
  • Practical guidance on initiating and adjusting insulin therapy

3. Getting primary care back on the road: diabetes care post-COVID-19

  • Prioritisation and addressing the backlog of care
  • Using audits and tools to optimise the use of limited resources
  • Variations in care – how can we begin to address them?

15 min break/Poster winner announcement

13.15-13.45

Session 3

Younger people: Everything you need to know in primary care

  • The challenge of making an accurate diagnosis in younger patients
  • Update on guidelines for managing diabetes in patients under 18
  • Engaging with adolescents and managing the transition to adulthood

15 min break

14.00-14.30

Symposia

15 min break

14.45-15.15

Diabetes Distilled

Emerging evidence from the weeks and months before the conference

15.15-15.25

Chair’s concluding remarks

Speakers

Headshot June 2021 2 (002)

Sarah Ali

Consultant Diabetologist, Royal Free London NHS Foundation Trust and South Asian Health Foundation (SAHF) Trustee

Peter-Bagshaw_SQ.jpg

Peter Bagshaw

General Practitioner, Associate Clinical Director for Mental Health, and Dementia and Learning disabilities at Somerset CCG

F_Place.png

Melissa Blow

Clinical Lead Podiatrist in Diabetes and Tissue Viability, Aneurin Bevan UHB

Pam_CRL.png

Pam Brown

GP, Swansea

Iain Cranston

Iain Cranston

Consultant Physician, Diabetes and Endocrinology Queen Alexandra Hospital, Portsmouth

Mark-Davies_1.png

Mark Davies

Consultant Clinical Psychologist, Belfast Health and Social Care Trust

Sarah-Davies_cropped.jpg

Sarah Davies

GP Partner, Cardiff

Jane Diggle

Jane Diggle

Specialist Practitioner Practice Nurse, West Yorkshire

Su_Down.png

Su Down

Diabetes Nurse Consultant, Somerset

Dr-Kevin-Fernando.jpg

Kevin Fernando

GPwSI in Diabetes and Medical Education, North Berwick

Claire_CRL.png

Clare Hambling

GP, Norfolk, and Chair of the PCDS

Lesley-Hamilton.png

Lesley Hamilton

Diabetes Dietitian and Diabetes Network Manager, Western Trust

Patrick-Holmes.jpg

Patrick Holmes

GP, Darlington

Naresh-Kanumilli-e1599055204247.png

Naresh Kanumilli

GP with Specialist Interest in Diabetes and Clinical Network Lead for Diabetes, Manchester

Kamlesh-Khunti.png

Kamlesh Khunti

Professor of Primary Care Diabetes and Vascular Medicine, Leicester

Stephen_Lawrence.png

Stephen Lawrence

GPSI, Kent and Associate Clinical Professor, Warwick University Medical School

F_Place.png

Jen Logue

Clinical Reader and Honorary Consultant in Metabolic Medicine

David Millar-Jones NEW

David Millar-Jones

GPwI in Diabetes, Cwmbran

Nicola.png

Nicola Milne

Community Diabetes Specialist Nurse, Manchester

Sam-Seidu_SQ.jpg

Sam Seidu

GP Partner, Leicester

Sanjay_Tanna.png

Sanjay Tanna

Lead Clinical Pharmacist, Blackpool

Conference sponsors

GOLD SPONSOR

Boehringer Ingelheim and Lilly Diabetes Alliance

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical needs

SILVER SPONSOR

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk

Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission.

To learn more, visit www.lilly.co.uk

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit www.novonordisk.co.uk

MASTERCLASS SPONSOR

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk

BRONZE SPONSOR

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products. For more information visit www.novonordisk.co.uk

Taking place on:

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.